A $1.8 billion acquisition of ArisGlobal allows Dassault Systèmes to integrate life sciences software into its AI strategy. The French firm confirmed its 2026 financial outlook following steady second-quarter revenue. This move targets specialized pharmaceutical data to refine industry-specific AI tools. It signals a shift toward high-value vertical integration over general software growth.